Published in J Am Soc Nephrol on February 23, 2005
Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 2.19
Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol (2006) 2.09
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr (2009) 1.61
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol (2014) 1.40
Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol (2012) 1.36
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol (2010) 1.30
The C-terminus of complement factor H is essential for host cell protection. Mol Immunol (2007) 1.14
Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) (2012) 1.10
Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun (2009) 1.07
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2008) 1.06
DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.05
Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol (2014) 1.05
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.03
Effects of Long Term Antibiotic Therapy on Human Oral and Fecal Viromes. PLoS One (2015) 1.02
Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol (2008) 1.01
Identification of the Shiga toxin-producing Escherichia coli O104:H4 strain responsible for a food poisoning outbreak in Germany by PCR. J Clin Microbiol (2011) 1.00
Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol (2013) 0.99
Transmembrane BAX inhibitor motif containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 synthase, and reduces Gb3 biosynthesis. J Biol Chem (2010) 0.99
Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatr Nephrol (2012) 0.97
Charged and hydrophobic surfaces on the a chain of shiga-like toxin 1 recognize the C-terminal domain of ribosomal stalk proteins. PLoS One (2012) 0.94
Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2014) 0.94
Haemolytic-uraemic syndrome as a sequela of diarrhoeal disease. J Health Popul Nutr (2012) 0.93
Renal complications of seasonal and pandemic influenza A virus infections. Eur J Pediatr (2012) 0.92
Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol (2011) 0.92
Renal transplantation in HUS patients with disorders of complement regulation. Pediatr Nephrol (2006) 0.91
Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategies. Front Cell Infect Microbiol (2012) 0.90
Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger? Pediatr Nephrol (2010) 0.87
Seasonal variation of HUS occurrence and VTEC infection in children with acute diarrhoea from Argentina. Eur J Clin Microbiol Infect Dis (2011) 0.87
Clinical aspects of a nationwide epidemic of severe haemolytic uremic syndrome (HUS) in children. Scand J Trauma Resusc Emerg Med (2011) 0.86
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther (2012) 0.86
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol (2014) 0.86
Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin. Infect Immun (2007) 0.86
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol (2007) 0.85
Endothelial health and diversity in the kidney. J Am Soc Nephrol (2006) 0.84
Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol (2007) 0.84
Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol (2014) 0.82
Kidney and urinary tract involvement in kawasaki disease. Int J Pediatr (2013) 0.82
A translational murine model of sub-lethal intoxication with Shiga toxin 2 reveals novel ultrastructural findings in the brain striatum. PLoS One (2013) 0.82
Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? Pediatr Nephrol (2011) 0.81
The metabolic enzyme AdhE controls the virulence of Escherichia coli O157:H7. Mol Microbiol (2014) 0.81
Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep (2015) 0.81
Combined effect of enterocin and lipase from Enterococcus faecium NCIM5363 against food borne pathogens: mode of action studies. Curr Microbiol (2012) 0.81
Regulation of nleA in Shiga toxin-producing Escherichia coli O84:H4 strain 4795/97. J Bacteriol (2010) 0.81
Common variable immunodeficiency complicated with hemolytic uremic syndrome. Ups J Med Sci (2011) 0.81
Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. PLoS Med (2006) 0.80
Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. AJP Rep (2016) 0.80
Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol (2014) 0.80
Thrombotic microangiopathy: E. coli O104:H4 German outbreak: a missed opportunity. Nat Rev Nephrol (2012) 0.79
Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol (2015) 0.79
C3 mesangial proliferative glomerulonephritis initially presenting with atypical hemolytic uremic syndrome: a case report. J Med Case Rep (2016) 0.79
Endothelial cells and thrombotic microangiopathy. Semin Nephrol (2012) 0.79
Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS One (2012) 0.79
Hemolytic uremic syndrome. Turk Pediatri Ars (2015) 0.79
Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence. Infect Dis Clin North Am (2013) 0.78
Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol (2011) 0.78
Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Crit Care Clin (2015) 0.78
Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ Case Rep (2013) 0.77
cblE-Type Homocystinuria Presenting with Features of Haemolytic-Uremic Syndrome in the Newborn Period. JIMD Rep (2012) 0.77
Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol (2009) 0.77
Assesment, treatment and prevention of atypical hemolytic uremic syndrome. Int J Prev Med (2013) 0.77
The challenge of managing hemophilia A and STEC-induced hemolytic uremic syndrome. Pediatr Nephrol (2012) 0.77
Hemolytic uremic syndrome after renal transplantation. Hippokratia (2006) 0.76
The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety? Toxins (Basel) (2012) 0.76
Clade 8 and Clade 6 Strains of Escherichia coli O157:H7 from Cattle in Argentina have Hypervirulent-Like Phenotypes. PLoS One (2015) 0.76
Hemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection. Pediatr Nephrol (2005) 0.75
CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol (2015) 0.75
Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection. CEN Case Rep (2012) 0.75
Hemolytic-Uremic Syndrome in Uberlândia, MG, Brazil. ISRN Pediatr (2011) 0.75
Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Rep Hematol (2015) 0.75
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab. Cureus (2017) 0.75
Overexpressed Proteins in Hypervirulent Clade 8 and Clade 6 Strains of Escherichia coli O157:H7 Compared to E. coli O157:H7 EDL933 Clade 3 Strain. PLoS One (2016) 0.75
Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern. Case Rep Nephrol (2016) 0.75
Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report. Medicine (Baltimore) (2017) 0.75
Quantitative Modeling of the Alternative Pathway of the Complement System. PLoS One (2016) 0.75
Recurrent hemolytic uremic syndrome. Indian J Nephrol (2008) 0.75
End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010. Hemodial Int (2015) 0.75
Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ (2016) 0.75
Complement regulation: physiology and disease relevance. Korean J Pediatr (2015) 0.75
Belatacept for Maintenance Immunosuppression in Lung Transplantation. J Investig Med High Impact Case Rep (2014) 0.75
Shifting the Paradigm in Hemolytic Uremic Syndrome. Pediatrics (2015) 0.75
Sub-Lethal Dose of Shiga Toxin 2 from Enterohemorrhagic Escherichia coli Affects Balance and Cerebellar Cytoarchitecture. Front Microbiol (2016) 0.75
Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep (2016) 0.75
Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. Proc (Bayl Univ Med Cent) (2017) 0.75
Severe form of hemolytic-uremic syndrome with multiple organ failure in a child: a case report. F1000Res (2014) 0.75
Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome. J Gen Intern Med (2015) 0.75
Hemolytic uremic syndrome caused by Bordetella pertussis infection. Pediatr Nephrol (2010) 0.75
Diffusion-weighted imaging of the kidneys in haemolytic uraemic syndrome. Eur Radiol (2017) 0.75
A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H. Pediatr Nephrol (2005) 0.75
Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep (2017) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol (2010) 1.85
Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care (2012) 1.85
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol (2003) 1.81
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int (2013) 1.81
In vivo maturation of functional renal organoids formed from embryonic cell suspensions. J Am Soc Nephrol (2012) 1.81
Mechanisms of disease: Pre-eclampsia. Nat Clin Pract Nephrol (2005) 1.79
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol (2012) 1.75
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol (2006) 1.74
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest (2015) 1.71
ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol (2011) 1.70
Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int (2002) 1.68
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int (2013) 1.68
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int (2013) 1.67
Eculizumab in a patient with dense-deposit disease. N Engl J Med (2012) 1.67
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Platelet dysfunction in renal failure. Semin Thromb Hemost (2004) 1.63
Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol (2009) 1.59
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood (2012) 1.58
Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol (2009) 1.54
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol (2005) 1.54
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol (2012) 1.54
Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev (2012) 1.53
Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. Am J Pathol (2013) 1.53
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol (2002) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Clinical update: immunosuppression minimisation. Lancet (2007) 1.50
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2007) 1.49
Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells (2010) 1.49
Treatment of chronic proteinuric kidney disease: what next? Hypertension (2009) 1.49
L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension (2004) 1.49
Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol (2002) 1.49
Doppler ultrasonography in posttransplant renal artery stenosis: a reliable tool for assessing effectiveness of revascularization? Transplantation (2003) 1.47
Kidney regeneration. Lancet (2010) 1.47
Mechanisms and treatment of CKD. J Am Soc Nephrol (2012) 1.46
Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol (2009) 1.45
Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med (2010) 1.44
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care (2010) 1.44
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J (2011) 1.43
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrol Dial Transplant (2003) 1.43
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol (2012) 1.42
Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int (2002) 1.42